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Practice variation in the use of tests in UK
primary care: a retrospective analysis of 16
million tests performed over 3.3 million
patient years in 2015/16
Jack W. O’Sullivan1,2* , Sarah Stevens2, Jason Oke2, F. D. Richard Hobbs2, Chris Salisbury3, Paul Little4,
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Abstract
Background: The UK’s National Health Service (NHS) is currently subject to unprecedented financial strain. The
identification of unnecessary healthcare resource use has been suggested to reduce spending. However, there is
little very research quantifying wasteful test use, despite the £3 billion annual expenditure. Geographical variation
has been suggested as one metric in which to quantify inappropriate use. We set out to identify tests ordered from
UK primary care that are subject to the greatest between-practice variation in their use.
Methods: We used data from 444 general practices within the Clinical Practice Research Datalink to calculate a
coefficient of variation (CoV) for the ordering of 44 specific tests from UK general practices. The coefficient of
variation was calculated after adjusting for differences between practice populations. We also determined the tests
that had both a higher-than-average CoV and a higher-than-average rate of use.
Results: In total, 16,496,218 tests were ordered for 4,078,091 patients over 3,311,050 person-years from April 1, 2015,
to March 31, 2016. The tests subject to the greatest variation were drug monitoring 158% (95%CI 153 to 163%), urine
microalbumin (52% (95%CI 49.9 to 53.2%)), pelvic CT (51% (95%CI 50 to 53%)) and Pap smear (49% (95%CI 48 to 51%).
Seven tests were classified as high variability and high rate (clotting, vitamin D, urine albumin, prostate-specific antigen
(PSA), bone profile, urine MCS and C-reactive protein (CRP)).
Conclusions: There are wide variations in the use of common tests, which is unlikely to be explained by clinical
indications. Since £3 billion annually are spent on tests, this represents considerable variation in the use of resources
and inefficient management in the NHS. Our results can be of value to policy makers, researchers, patients and
clinicians as the NHS strives towards identifying overuse and underuse of tests.
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Introduction
Healthcare systems around the world are struggling to
remain fiscally sustainable [1–3]. With increases in
spending, healthcare systems are faced with a mismatch
between funding and expenditure [4, 5].
To help reduce costs, the identification of unnecessary
care has become a focus of governments and healthcare
funders around the world [6]. Primary care accounts for
most health care (90% of all UK National Health Service
(NHS) care [7], 55% in the USA [8]) and serves a gate-
keeper function in the UK; tests often have knock-on
consequences in both primary and secondary care. As
such, the identification of wasteful resource use in primary
care has implications for the entire healthcare system.
Previous research has suggested that when there is
strong evidence and a professional consensus that an
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intervention is effective, there tends to be almost no
variation in practice [9, 10]. Conversely, variation in the
use of resources has been used to highlight possible
overuse or underuse [10, 11].
Despite its contribution to care and expenditure [12],
there is little research into variation in the use of tests
by general practitioners (GPs). UK GPs are thought to
spend more than £3 billion annually on tests [12]. One
study has explored variation in GP test use, but it fo-
cused on a few specific tests in a relatively small popu-
lation [13]. We set out to identify which tests are




We obtained electronic health record data from patients
registered with general practices contributing to the
Clinical Practice Research Datalink (CPRD) during April
1, 2015, to March 31, 2016. The CPRD, a large database
of anonymised electronic health records from UK pri-
mary care, contains patient-level data covering approxi-
mately 7% of the UK population [14]. CPRD data have
been validated extensively and are representative of the
UK population in terms of age, sex [14], and ethnic
background [15]. We included patients of any age if
their records were acceptable for research purposes (a
data quality indicator provided by CPRD) and were reg-
istered at practices with continuous high-quality data
reporting (CPRD defined up-to-standard) [16] at any
time during the study period. We grouped patient data
into their respective general practices.
The protocol was approved by the Independent Scien-
tific Advisory Committee (ISAC) of the MHRA (ISAC
protocol number 17_06R). Ethics approval for observa-
tional research using the CPRD with approval from
ISAC was granted by a National Research Ethics Service
committee (Trent MultiResearch Ethics Committee,
REC reference number 05/MRE04/87).
Included tests
We examined 44 specific tests (28 laboratory, 11 im-
aging and 5 other miscellaneous tests). The tests were
chosen because they are commonly used tests or in-
cluded in the guidelines or in the Quality Outcomes
Framework (QOF) (Additional file 1: "Extended included
tests" section).
We grouped tests into their respective general prac-
tices, via their practice identification number. To avoid
double counting, if the same code was recorded multiple
times for the same patient on the same day, it was
counted as only one test. Similarly, codes likely referring
to the same test, or separate components of a single test
(e.g. individual components of a full blood count), were
grouped and counted as one test.
Statistical analysis
To identify which test was subject to the greatest
between-practice variation in its use, we calculated, for
each 44 tests, an unadjusted coefficient of variation
(CoV) and then an adjusted CoV.
To calculate the unadjusted coefficient of variation, we
did the following: we initially determined the number of
tests ordered from each practice from April 1, 2015, to
March 31, 2016. We then calculated the total person-years
of observation for each general practice. Patients alive and
registered for the entire year contributed 1 person-year of
observation to the total. Patients who were born, died,
registered, or deregistered during the year were included,
but their contribution to the person-year calculation was
adjusted proportionately (e.g. a patient who was registered
and alive for only 6months contributed 0.5 person-years).
We then calculated the mean unadjusted rate of use
for each specific test across all 444 general practices; we
also calculated the corresponding standard deviation.
We used these two numbers to calculate the unadjusted
CoV (standard deviation/mean × 100) [17]. The use of
CoV facilitates a direct comparison of the variation in
use between tests controlling for differences in sample
size. It is expressed as a percentage (the ratio of the
standard deviation to the mean), with larger percentages
reflecting greater variation.
To calculate the adjusted CoV, we constructed a general-
ised linear model with Poisson errors to estimate the num-
ber of tests ordered from each general practice adjusted for
practice differences in patient age, sex and deprivation. We
constructed 44 Poisson models for each test. The age co-
variate represents the median age of each general practice,
the sex covariate represents the proportion of female pa-
tients in each practice and the deprivation covariate repre-
sents the practice-level Index of Multiple Deprivation
(IMD) deciles. We constructed Poisson models to adjust
for differences in patient demographics (age, sex and IMD)
between general practices. We did not construct Pois-
son models to compare the predictive ability of patient
demographics on the rates of test use.
We then calculated the adjusted rate of use for each test
in every general practice by dividing the adjusted number
of tests by the person-years for each general practice (the
same process we followed to calculate the unadjusted rate
of use). The adjusted rates were used to calculate the
adjusted CoV for each test, as described above [17]. We
ranked tests according to their CoV. We present both
the unadjusted and adjusted CoV in Additional file 1,
but only the adjusted CoV in the main manuscript.
To identify the tests that had both a high rate of use
and a high CoV, we calculated the overall median rate of
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test use and the overall median adjusted CoV. We then
classified tests into four categories: (1) high variability,
low rate, (2) high variability, high rate, (3) low variability,
low rate or (4) low variability, high rate. These categories
reflect a test’s measure in relation to the median value,
e.g. high variability, low rate refers to tests with a coeffi-
cient of variation above the median coefficient of variation,
but a rate of test use below the median rate of test use.
Role of the funding source
This study was funded by an independent grant from
the National Institute for Health Research (NIHR) School
of Primary Care Research (Grant reference number 386)
and the Primary Care Research Trust. Independent expert
peer reviewers provided feedback on the grant application
underpinning this study but had no further role in study
design, data collection, analysis, interpretation or drafting
of the manuscript.
Results
Data from 444 general practices contributed to the CPRD
from April 1, 2015, to March 31, 2016. In total, 16,496,218
tests were ordered for 4,078,091 patients over 3,311,050
person-years. The median age of patients was 40 (IQR 21
to 58) and the median percentage of females was 50.6%
(IQR 49.7 to 51.3%). The total number of patients that each
practice contributed varied (median 6955 (IQR 4374 to
9905), and deprivation differed between included general
practice, ranging from 1 to 10 (median 6 (IQR 4 to 8)).
Tests with the most variation in use
Figure 1 shows the rank order of the most to least vari-
able tests. The adjusted CoV varied from 158% (95%CI
153 to 163%) for non-illicit drug monitoring tests (urine,
blood or serum, for instance serum digoxin or lithium)
to 5.6% (95%CI 5.4 to 5.8%) for testosterone tests. Urine
microalbumin (52% (95%CI 49.9 to 53.2%)), pelvic CT
(51% (95%CI 50 to 53%)) and Pap smear (49% (95%CI
48 to 51%) were the second, third and fourth most vari-
able tests. Drug monitoring, pelvic CT and Pap smear
tests were also the most variable laboratory, imaging and
miscellaneous tests respectively. The median coefficient
of variation was 22.7% (IQR 14.8 to 31.0%). These mea-
sures represent the between-practice variation in test or-
dering adjusted for age, sex and deprivation differences
between practices (Additional file 1: Table S1).
Additional file 1: Figure S1 shows the adjusted and un-
adjusted coefficients of variation for the 44 specific tests,
and Additional file 1: Table S1 presents the difference
between adjusted and unadjusted coefficients of vari-
ation for each specific test. Figure 2 shows an example
of the adjusted and unadjusted rate of test use (CRP),
measured against the respective person-years. This fig-
ure shows how the rates of CRP use for each 444 general
practices is adjusted in accordance to their practice
demographic (age, sex and deprivation). Similar graphs
for the other 43 tests are displayed in Additional file 1
(page 10 onwards).
Tests with a high rate of use and high variability of use
Figure 3 plots the adjusted coefficient of variability of
each test against its respective rate. The median rate was
167.3 (per 10,000 person-years) and the median CoV
was 22.7. Most tests were classified as high variability,
low rate (n = 15, 34%) or low variability, high rate (n = 15,
34%). Seven tests were classified as high variability and
high rate (clotting, vitamin D, urine albumin, prostate-spe-
cific antigen (PSA), bone profile, urine MCS and
C-reactive protein (CRP)). The remaining seven tests were
classed as low variability and low rate.
Four miscellaneous tests were in the same category
(high variability, low rate: colonoscopy, upper endos-
copy, Pap smear and vaginal swab), with only one (spir-
ometry) classed as low variability, high rate. Ten of the
11 imaging tests had rates of use below the median; four of
these tests were classified as low variability and low rate
(pelvic ultrasound, lumbar X-ray, knee X-ray and echocar-
diogram), while the other six were classified as high vari-
ability, low rate (pelvic CT, knee MRI, DEXA, brain MRI,
brain CT and lumbar spine MRI). Only one imaging test
had an adjusted rate above the median (chest X-ray), which
was classified as low variability, high rate. Additional file 1:
Table S2 shows the classification of all tests.
Discussion
We present a ranking of 44 primary care tests based on
the between-practice variation in their use. We analysed
over 16 million tests from 444 general practices and
ranked tests by their adjusted coefficient of variation.
The test subject to the greatest variation was non-illicit
drug monitoring tests (urine, blood or serum), urine
microalbumin, pelvic CT, and Pap smear. We also iden-
tified seven tests with both a rate of ordering and a coef-
ficient of variation above average: clotting, vitamin D,
urine albumin, PSA, bone profile, urine MCS and CRP.
Strengths and limitations in relation to previous research
Our analysis adjusted for demographic differences be-
tween practices; however, there may be valid reasons to
explain the residual variation we present. Previous work
has suggested that differences in disease prevalence, pa-
tient choice, data artefact (differences in data quality), re-
source availability, local policy and guidelines, and service
configurations may also contribute to variation in health-
care resource use [10]. Other previous research suggests
further reasons, not all justifiable. The influence of local
key-opinion leaders [18]—such as a hospital consultant
preferring a one test over another—and the variation in
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Fig. 1 Rank order of variability of tests, adjusted for age, sex and deprivation. CT = Computer Tomography, MRI = Magnetic Resonance Imaging,
PSA = Prostate Specific Antigen, DEXA = Dual-energy X-ray absorptiometry, CRP = C-reactive Protein, MCS = Microscopy, culture and sensitivities,
ACR = Albumin-creatinine ratio, ESR = Erythrocyte sedimentation rate, LFT = Liver Function Tests, FBC = Full Blood Count
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management of uncertainty among general practitioners
[19] have both been suggested as contributors.
We used the conventional statistical analysis for count
data, a Poisson regression model. However, we used the
outputs of this model in a less conventional manner.
The aim of this paper was to determine which tests were
subject to the most between-variation practice in their
use once patient demographics between practices had
Fig. 2 Adjusted and unadjusted rates for C-reactive Protein (CRP) use. All 444 practices are represented by one red and one blue data point
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been accounted for. We did not use the Poisson models
to determine and compare the predictive ability of our
covariates (patient demographics). As is expected when
analysing health care data [20], the model accounted for
some, but not all, of the variation in test use. This re-
sidual variation—“overdispersion”—represents the vari-
ation in test use once patient demographics between
practices had been accounted for. We ranked tests by
their residual variation; variation in use that persisted
despite adjustment of patient demographic differences
between practices.
A strength of our study is our examination of all types of
tests (imaging, laboratory and miscellaneous), inclusion of
many tests and our use of the appropriate statistical
methods to quantify variation. One previous study has pre-
sented a ranking of primary care tests on their between-
practice variation [13]. This study only examined labora-
tory tests and included a smaller number of tests [21] in a
smaller sample of patients. This study also ranked test vari-
ation by their standard deviation (SD). We preferred CoV
to SD because SD is affected by the rate of testing (sample
size). We found that tests that are most commonly ordered
are more likely to have higher standard deviations. The use
of SD to rank the between-practice variation may make
tests that are ordered more commonly appear to have
higher between-practice variation. A limitation of our use
Fig. 3 Variability and rates of tests. The vertical line represents the median rate of test use and the horizontal line represents the median
coefficient of variation. Median rate (vertical line) = 167.3. Median CoV (horizontal line) = 22.7
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of CoV is that it may overestimate variation in low ordering
tests; to try and mitigate this, we presented both the tests
with the greatest between-practice variation and the tests
with a rate of ordering and a CoV above average. We
believe tests with both a high CoV and high rate of ordering
should be the focus of future academic and policy work.
A further strength of our study is the use of high-qual-
ity, validated electronic health record data and the iden-
tification of tests that are subject to the greatest
between-practice variation. Most previous research ex-
ploring geographical variation in healthcare resource use
has focused on identifying regions that order a greater
or lesser number of tests or treatments compared to the
national average [11, 22–25].
Implications for practice and policy
The wide between-practice variation in test use we
present is unlikely to be explained entirely by clinical
indication. We present a list of common and important
primary care tests ranked by their between-practice
variation. Policy makers must decide if the residual
variation we present is warranted, and if it is not,
understand why this variation exists and what can be
done to mitigate it. Between-practice variation and,
more broadly, geographical variation have long been
used to highlight potential over or underuse of health-
care resources [6, 24, 26, 27]. Our ranking of tests can
direct policy makers to the primary care tests most
likely subject to overuse—the use of a test when it will
not result in patient benefit—or underuse—the failure
to use a test when it would result in patient benefit.
However, it should be noted the variation we present
does not directly consider individual patient data nor
the clinical indications for test use. As such, our results
can be considered a potential, not definitive, indicator
of over and underuse.
In some cases, there are content-specific reasons to
explain the between-practice variation in test use. For
instance, the notable between-practice variation in the
use of clotting and drug monitoring tests may reflect re-
gional differences in drug use. In UK primary care, there
has been an increase in the use of novel oral anticoagu-
lants (NOAC) (also known as direct acting oral antico-
agulants (DOACs) [28]; from 2009 to 2015, there was a
17-fold increase in NOAC use [28]. However, there is
marked geographical variation in their use [21]. This
variation may reflect the non-specific NICE guidance; it
states that patients with atrial fibrillation can be anti-co-
agulated with “apixaban, dabigatran, rivaroxaban or a
vitamin K antagonist” [29]. However, this guidance is
now out-of-date compared to more recent evidence. A
2017 systematic review and network meta-analysis con-
cluded that “the risk of all-cause mortality was lower
with all DOACs” and “several DOACs are of net benefit
compared with warfarin” [30]. With clear guidance,
reflecting the underlying evidence, it is plausible that
geographical variation in clotting tests would diminish.
Similarly, the variability of drug monitoring tests is
likely to be related to regional differences in disease
prevalence. Drug monitoring tests include tests for
tacrolimus, cyclosporin, salicylate, lamotrigine, lithium
and gentamicin (among others). All of these tests, indi-
vidually, had low rates of use. Lastly, it should be noted
that tests can be directly wasteful, but can also contrib-
ute to healthcare costs indirectly, for instance via inci-
dental imaging findings [31].
Future research
It would be advantageous for future studies to investi-
gate variation using a different unit of an analysis. We
chose to investigate variation at a practice level; however,
future studies could investigate variation at a patient level
or at a regional level. We chose to investigate at a practice
level as previous literature suggests practice-level factors
contribute substantially to healthcare variation [10, 18].
Differences in disease prevalence, cultural attitude to
tests and their risks, local key-opinion leaders, resource
availability, local policy and guidelines, and service
configurations have all been suggested as practice-level
contributors to variation.
A similar analysis aggregated at a regional, rather
than practice, level may provide further insight into
unwarranted variation. It is plausible that our analysis
at a practice level may be too sensitive to variation in
disease prevalence; this may in part explain non-illicit
drug testing as an outlier. However, the aggregation of
data at a regional level may obfuscate true, unwar-
ranted variation. Furthermore, the CPRD only allows
practices to be identified at a broad regional level (e.g.
within Wales). Conversely, future research that analyses
data at an individual patient level may provide more nu-
anced insight into variation, but risks being overly sensi-
tive, making the distinction between warranted and
unwarranted variation more difficult. Nevertheless, we
would welcome any further studies that adopted any of
the aforementioned units of analyses.
Furthermore, beyond adjustment for demographic differ-
ences, we could not directly determine the appropriateness
of the between-practice variation we noted. Future research
studies should aim to determine if the tests with the great-
est between-practice variation are also subject to the great-
est underuse and overuse. This research should ideally
involve individual patient data (IPD) either in the form of
notes review, or IPD data audit [32], commonly against
guidelines [33]. Finally, some of our team are involved in
delivering OpenPathology.net [24]; an open data tool (like
OpenPrescribing.net) that provides easy access to various
analytic approaches identifying test-ordering behaviour in
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primary care. This tool will continue our work exploring
temporal trends on a live interface.
Conclusions
There is wide variation among commonly used tests,
which is unlikely to be explained by clinical indication,
and since £3 billion annually are spent on tests, this rep-
resents considerable resource use variation and ineffi-
cient management for the NHS.
Additional file
Additional file 1: Additional methods and results. (DOCX 725 kb)
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